IDRI & USAID Form Collaboration for Malaria Vaccine Development

The collaboration is for the development of a novel malaria vaccine, which combines WRAIR's malaria antigen CelTOS with IDRI's potent GLA-SE adjuvant.

The Infectious Disease Research Institute (IDRI) announced Tuesday a new Memorandum of Understanding with the United States Agency for International Development (USAID), focused on support of a collaboration with the Walter Reed Army Institute of Research (WRAIR) for the development of a new vaccine against malaria. 

The collaboration is for the development of a novel malaria vaccine, which combines WRAIR's malaria antigen CelTOS with IDRI's potent GLA-SE adjuvant. 

Preclinical studies have shown that the combination of CelTOS and GLA-SE in a vaccine candidate produces potent immune responses in small animals, resulting in a protective immune response during the infectious mosquito-stage of malaria parasites.